Custom service
Cyclic Peptide Drug Development
Take a cyclic peptide lead through developability assessment
Teams come to this service when they need to take a cyclic peptide lead through developability assessment. We typically start from developability profiling (solubility, stability, aggregation), add formulation screening where the application demands it, and close the loop with analytical method package so the final developability report with recommended form behaves consistently across lots.
Design reviews are part of the schedule, not an extra. Sequence, spacer architecture and analytical strategy are signed off before the first synthesis run, which is why the 8–14 weeks timeline holds in practice.
Pre-IND cyclic lead assessment
Cyclic peptide manufacturing route scouting
IND-enabling toxicology and GLP studies
Cycles whose ring size is known to be geometrically uncloseable
Cyclic products are released against connectivity, not mass alone. MS/MS fragmentation confirms the ring closure, and where multiple topologies are possible the target isomer is isolated and its ratio reported. Protease-stability data are available as an add-on.
Service Highlights
- Developability profiling (solubility, stability, aggregation) as the default route, with formulation screening held as a proven fallback
- Analytical method package worked into the design where the application requires it
- Cyclization strategy (head-to-tail, disulfide, lactam, thioether) chosen from a feasibility screen, not fixed by habit
- Analytical confirmation of every intermediate before the final release
- Cyclic/linear and topological isomers separated and reported, with the target isomer identified by MS/MS
- Developability report with recommended form delivered with a complete conjugation or synthesis certificate
How the work runs
Precursor design
Linear precursor, cyclization sites and protecting strategy are designed around the Cyclic Peptide Drug Development ring size.
Linear assembly
The precursor chain is assembled with Fmoc chemistry and developability profiling (solubility, stability, aggregation) where relevant.
Cyclization
Ring closure is executed by formulation screening under screened dilution and activation conditions.
Isomer separation
RP-HPLC resolves cyclic/linear and topological isomers; the target isomer is collected.
Characterization
Connectivity, purity and identity are confirmed by MS/MS and HPLC against the specification.
Release
Developability report with recommended form is documented and released after QC sign-off.
Specifications & timeline
- Turnaround
- 8–14 weeks
- Typical scale
- 1 – 200 mg cyclic peptide
- Chemistry options
- developability profiling (solubility, stability, aggregation); formulation screening; analytical method package
- Deliverable
- Developability report with recommended form
- QC package
- HPLC purity, MS/MS connectivity proof, isomer ratio, DMSO solubility
- Shipping
- Ambient with desiccant; blue ice for sensitive motifs
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.